Los derechos de propiedad genética en los tribunales

LONDRES – A primeros de febrero de 2010, un tribunal federal de distrito de los Estados Unidos en Nueva York empezó a dilucidar una causa decisiva sobre si las personas tienen “derecho a saber” cómo puede su genoma dictar su salud futura. La causa - American Civil Liberties Union contra Myriad Genetics” - puede tener repercusiones transcendentales en la medicina y la ciencia.

Las cuestiones en torno a las cuales gira la causa son las de si las patentes genéticas ayudan o entorpecen la investigación y si los pacientes deberían pagar los derechos correspondientes a una empresa biotecnológica para que analizara su predisposición a las enfermedades.

Uno de los demandantes es Lisbeth Ceriani, una mujer de 43 años con cáncer de mama cuyos doctores recomendaron que se le hicieran exámenes sobre dos mutaciones genéticas relacionadas con algunas formas hereditarias de la enfermedad. Myriad Genetics, la única empresa que hace esos análisis en los EE.UU. –es titular de una patente sobre los genes mismos y no sólo sobre el análisis diagnóstico– no aceptó su seguro y Cariani no pudo costearse el examen. De modo que no pudo conocer esa información, como tampoco sus médicos, cosa que podía tener consecuencias para su tratamiento clínico. Otros cinco demandantes –junto con importantes órganos médicos– cuentan historias similares.

To continue reading, please log in or enter your email address.

Registration is quick and easy and requires only your email address. If you already have an account with us, please log in. Or subscribe now for unlimited access.


Log in

  1. An employee works at a chemical fiber weaving company VCG/Getty Images

    China in the Lead?

    For four decades, China has achieved unprecedented economic growth under a centralized, authoritarian political system, far outpacing growth in the Western liberal democracies. So, is Chinese President Xi Jinping right to double down on authoritarianism, and is the “China model” truly a viable rival to Western-style democratic capitalism?

  2. The assembly line at Ford Bill Pugliano/Getty Images

    Whither the Multilateral Trading System?

    The global economy today is dominated by three major players – China, the EU, and the US – with roughly equal trading volumes and limited incentive to fight for the rules-based global trading system. With cooperation unlikely, the world should prepare itself for the erosion of the World Trade Organization.

  3. Donald Trump Saul Loeb/Getty Images

    The Globalization of Our Discontent

    Globalization, which was supposed to benefit developed and developing countries alike, is now reviled almost everywhere, as the political backlash in Europe and the US has shown. The challenge is to minimize the risk that the backlash will intensify, and that starts by understanding – and avoiding – past mistakes.

  4. A general view of the Corn Market in the City of Manchester Christopher Furlong/Getty Images

    A Better British Story

    Despite all of the doom and gloom over the United Kingdom's impending withdrawal from the European Union, key manufacturing indicators are at their highest levels in four years, and the mood for investment may be improving. While parts of the UK are certainly weakening economically, others may finally be overcoming longstanding challenges.

  5. UK supermarket Waring Abbott/Getty Images

    The UK’s Multilateral Trade Future

    With Brexit looming, the UK has no choice but to redesign its future trading relationships. As a major producer of sophisticated components, its long-term trade strategy should focus on gaining deep and unfettered access to integrated cross-border supply chains – and that means adopting a multilateral approach.

  6. The Year Ahead 2018

    The world’s leading thinkers and policymakers examine what’s come apart in the past year, and anticipate what will define the year ahead.

    Order now